Publications by authors named "M Mar Abad-Hernandez"
Article Synopsis
- Luminal A breast cancer has a good outlook, but around 10% of patients may have tumors come back after 10 years, especially within the first 5 years after diagnosis.
- A study was done to see how a specific protein called NCAPH affects the growth of luminal A breast cancer, looking for gene patterns that could indicate a higher risk of bad outcomes.
- The findings showed that high levels of NCAPH are linked to more aggressive tumors and poorer responses to chemotherapy, leading to a new gene score (GSLA10) that can help predict which patients might have worse outcomes.
Introduction: Apremilast is approved for treatment of psoriasis and psoriatic arthritis (PsA). Real-world evidence on apremilast effectiveness in clinical practice is limited.
Methods: Observational study enrolling adult patients, across 21 Spanish centres, who had initiated apremilast in the prior 6 (±1) months and were biologic naive.
Despite their generally favorable prognosis, luminal A tumors paradoxically pose the highest ten-year recurrence risk among breast cancers. From those that relapse, a quarter of them do it within five years after diagnosis. Identifying such patients is crucial, as long-term relapsers could benefit from extended hormone therapy, whereas early relapsers may require aggressive treatment.
View Article and Find Full Text PDFIn recent years, non-small cell lung cancer treatment has been revolutionized. tyrosine kinase inhibitors and our improved understanding of its alterations have driven new diagnostic strategies. Liquid biopsies have emerged as a useful tool in these contexts, showing potential utility in early diagnosis combined with low-dose CT scans, as well as potential in monitoring treatment response and predicting the development of patients.
View Article and Find Full Text PDFSER-SEPAR recommendations for the management of rheumatoid arthritis-related interstitial lung disease. Part 1: Epidemiology, risk factors and prognosis.
Reumatol Clin (Engl Ed)
October 2022
Objective: To develop multidisciplinary recommendations to improve the management of rheumatoid arthritis-related interstitial lung disease (RA-ILD).
Methods: Clinical research questions relevant to the objective of the document were identified by a panel of rheumatologists and pneumologists selected based on their experience in the field. Systematic reviews of the available evidence were conducted, and evidence was graded according to the Scottish Intercollegiate Guidelines Network (SIGN) criteria.